Page results
-
Details of the charity and voluntary sector services.
-
Ensuring that UCLH staff understand the urgency of the climate crisis and support our net zero programme is crucial if we want to be successful in reaching our goal of net zero carbon emissions by 2031. Our patients must be kept informed of changes and we must work closely with other NHS organisations, including NHS England, if we are to deliver a successful programme. This page documents our progress to date.
-
UCLH needs to reduce the amount we consume per patient, re-use and re-manufacture what we can and ensure that what we do use has minimal environmental impact. We also need to ensure our suppliers match our environmental ambitions. This page explores our progress so far.
-
UCLH has received the highest score of all general acute and acute/community NHS trusts in England for staff that would recommend us as a place to work for two years running.
-
Delivering vital interventions, medicines and all other healthcare services are responsible for a major part of the NHS’s carbon emissions. We need to redesign our services to reduce their environmental impact, whilst maintaining the highest standards of care delivery. This page outlines our progress so far.
-
As an organisation, UCLH needs to minimise the environmental impact of our buildings and the energy they use and maximise our use of any technology available to support these changes. This page outlines our progress to date.
-
As part of Our National Health Stories, University College London Hospitals NHS Foundation Trust commissioned five poets to write and share stories from the NHS.
-
The National Hospital for Neurology and Neurosurgery’s Professor Tabrizi is amongst a small number of exceptional researchers from across the world elected to the Fellowship of the Royal Society today.
-
Our staff have rated UCLH as the top trust in England, improving on our ranking from last year when we were third best in England and top in London.
-
UCLH is contributing to a national priority trial of the drug ruxolitinib in patients with Covid-19 pneumonia (infection of the lungs).
File results
-
FOI/2022/0150 - Hepatocellular carcinoma drug treatments
-
FOI/2022/0161 - Referral to treatment waiting times
-
FOI/2022/0163 - Ongoing staff absence due to COVID-19
-
FOI/2022/0166 - Routine GP referrals made to Cardiology, Gynaecology and Neurology
-
FOI/2022/0171 - Consultant-led Referral to Treatment (RTT), outpatients and Patient Initiated Follow-up (PIFU)
-
FOI/2022/0186 - Gender neutral toilets at the Trust
-
FOI/2022/0211 - Enteral feeding machine mechanical insufflator
-
FOI/2022/0216 - Inventory management system
-
FOI/2022/0217 - Medications for dermatological conditions
-
FOI/2022/0227 - Number of cancer trackers and cancer MDT co-ordinators at Trust